15. 封入体筋炎 Disease details / Clinical trials / Drug dev / DR info

ABC008
   Abcuro, Inc.
      2024   Phase 2/Phase 3   NCT06450886   Australia;United States
      2023   Phase 2/Phase 3   NCT05721573   Australia;Belgium;Canada;France;Germany;United Kingdom;United States
      2021   Phase 1   NCT04659031   Australia
Adsvf
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 1   NCT05032131   France
Alemtuzumab
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00079768   United States
Anakinra
   Karolinska Institutet
      2003   Phase 2/Phase 3   NCT01165008   Sweden
Arimoclomol
   Orphazyme
      2019   Phase 3   NCT04049097   United Kingdom;United States
      2017   Phase 2   NCT02753530   United Kingdom;United States
   Richard Barohn, MD
      2008   Phase 2/Phase 3   NCT00769860   United Kingdom;United States
   UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
      2009   Phase 2   EUCTR2008-008208-42-GB   United Kingdom
Arimoclomol citrate
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000749-11-GB   United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-004903-33-GB   United Kingdom;United States
Bimagrumab
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2015-001411-12-IT   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-000705-23-IT   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
   Novartis Pharma K.K.
      2015   Phase 2-3   JPRN-jRCT2080223024   -
      2013   Phase 2-3   JPRN-jRCT2080222316   -
   Novartis Pharma Services AG
      2015   Phase 3   EUCTR2015-001411-12-NL   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-GB   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-FR   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-DK   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-BE   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
   Novartis Pharmaceuticals
      2015   Phase 3   NCT02573467   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2014   Phase 2/Phase 3   NCT02250443   United States
Blood draw FOR optional genetic exome sequencing
   LMU Klinikum
      2022   -   NCT05272969   Germany
Blood-flow restricted training
   University of Southern Denmark
      2015   -   NCT02317094   Denmark
Borg scale
   LMU Klinikum
      2022   -   NCT05272969   Germany
Botulinum toxin type A
   Rigshospitalet
      2014   Phase 2   EUCTR2014-002210-23-DK   Denmark
BRX-345
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000749-11-GB   United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-004903-33-GB   United Kingdom;United States
   UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
      2009   Phase 2   EUCTR2008-008208-42-GB   United Kingdom
BYM338
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2015-001411-12-IT   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-000705-23-IT   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
   Novartis Pharma K.K.
      2015   Phase 2-3   JPRN-jRCT2080223024   -
      2013   Phase 2-3   JPRN-jRCT2080222316   -
   Novartis Pharma Services AG
      2015   Phase 3   EUCTR2015-001411-12-NL   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-GB   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-FR   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-DK   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-BE   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2014   -   EUCTR2013-000705-23-NL   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-000705-23-GB   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-000705-23-DK   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-000705-23-DE   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
      2014   -   EUCTR2013-000705-23-BE   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
   Novartis Pharmaceuticals
      2014   Phase 2/Phase 3   NCT02250443   United States
      2011   Phase 2   NCT01423110   United States
BYM338/bimagrumab
   Novartis Pharmaceuticals
      2013   Phase 2/Phase 3   NCT01925209   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
Care AS usual
   University of Southern Denmark
      2015   -   NCT02317094   Denmark
Etanercept
   Washington University School of Medicine
      2005   Phase 0   NCT00802815   United States
Gamma globulin
   National Institute of Neurological Disorders and Stroke (NINDS)
      1990   Phase 2   NCT00001261   United States
Genetic test: ACE polymorphism
   LMU Klinikum
      2022   -   NCT05272969   Germany
Genetic test: ACTN3 polymorphism
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: calcium
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: creatine kinase
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: magnesium
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: phosphate
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: vitamin D level
   LMU Klinikum
      2022   -   NCT05272969   Germany
Muscle ultrasound
   LMU Klinikum
      2022   -   NCT05272969   Germany
Natalizumab
   Phoenix Neurological Associates, LTD
      2013   Phase 1   NCT02483845   United States
Phenylbutyrate oral tablet
   University of Kansas Medical Center
      2020   Phase 1   NCT04421677   United States
Pioglitazone
   Johns Hopkins University
      2018   Phase 1   NCT03440034   United States
Pozelimab/cemdisiran
   Austin Neuromuscular Center
      2024   Early Phase 1   NCT06479863   United States
Pressure pain threshold
   LMU Klinikum
      2022   -   NCT05272969   Germany
Quick motor function test
   LMU Klinikum
      2022   -   NCT05272969   Germany
RAAV1.CMV.hufollistatin344
   Nationwide Children's Hospital
      2012   Phase 1   NCT01519349   United States
Rapamycin
   Institut National de la Santé Et de la Recherche Médicale, France
      2015   Phase 2/Phase 3   NCT02481453   France
REGN2477+REGN1033
   Regeneron Pharmaceuticals
      2019   Phase 2   NCT03710941   -
Ruxolitinib
   Assistance Publique - Hôpitaux de Paris
      2025   Phase 2   NCT06536166   -
Simvastatin
   ISTITUTO NEUROLOGICO CARLO BESTA
      2007   -   EUCTR2007-004359-12-IT   Italy
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2007   -   EUCTR2006-005942-35-IT   Italy
Sirolimus
   University of Kansas Medical Center
      2022   Phase 3   NCT04789070   Australia;United States
Sivastin
   ISTITUTO NEUROLOGICO CARLO BESTA
      2007   -   EUCTR2007-004359-12-IT   Italy
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2007   -   EUCTR2006-005942-35-IT   Italy
Ulviprubart
   Abcuro, Inc.
      2024   Phase 2/Phase 3   NCT06450886   Australia;United States
Vital signs
   LMU Klinikum
      2022   -   NCT05272969   Germany
Xeomin
   Rigshospitalet
      2014   Phase 2   EUCTR2014-002210-23-DK   Denmark